Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Sandoz Inc.
WARNING LETTER
•Sandoz Inc.•March 31, 2008

Sandoz Inc. – FDA Warning Letter, Mar 31, 2008

Record Details

The FDA issued a Warning Letter to Sandoz following a March 2008 inspection of their Wilson, NC facility, revealing significant Current Good Manufacturing Practice (CGMP) deviations in the manufacturing of drug products, including Metoprolol Succinate ER tablets, rendering them adulterated. Key violations cited include the failure to establish and follow written procedures for process control, specifically inadequate validation of the Metoprolol manufacturing process (21 CFR § 211.100(a)). The firm also failed to thoroughly investigate unexplained discrepancies or batch failures (21 CFR § 211.192), with numerous investigations delayed or incomplete. Further deficiencies involved not including in-process and laboratory control results in batch records (21 CFR § 211.188(b)(5)), incomplete master production and control records (21 CFR § 211.186(b)(9)), and inadequate laboratory controls for specifications (21 CFR § 211.160(b)), including the release of non-conforming lots. Critical data integrity issues were identified, with computer systems lacking controls to prevent modification or deletion of raw data and no audit trails (21 CFR § 211.68(b)). The Quality Control Unit (QCU) was found to have failed in its responsibilities, including ensuring investigations and process validation (21 CFR § 211.22(d)). The FDA expressed concerns about the continued distribution of Metoprolol and the lack of a global approach to quality. Sandoz must provide a written response within 15 working days detailing corrective actions and their prevention of recurrence, with potential regulatory actions including disapproval of applications if deficiencies are not corrected.

Company
Sandoz Inc.
Inspection date
March 31, 2008
Office
Atlanta District Office
People
  • Mary H. Woleske
  • Bill Monteith (Independent Director)
View Company Profile

ID · e78e0997-364b-452b-aa97-32873a78f9f6

Violation Codes3
21 CFR 21021 CFR 211FD&C Act 501(a)(2)(B)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Sandoz Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.